Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

大型3型/4型胃癌に対する術前S-1+Oxaliplatin+ Docetaxel併用療法の有効性と安全性確認第II相試験(OGSG1902)短期成績報告

高度リンパ節転移を伴う進行胃癌に対する周術期 Capecitabine＋Oxaliplatin療法の第II相試験（OGSG1701）

RINDBeRG試験におけるラムシルマブの投与タイミングにおけるサブグループ解析

Effects of an oral elemental nutritional supplement for gastric cancer with adjuvant S-1 therapy（Phase II trial: OGSG1108）

Short‑term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)

A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701)

Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: a randomized clinical trial in third or further-line treatment of gastric cancer

The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).